PolyPEPI1018

About Treos Bio

Treos Bio is pioneering a novel approach to active cancer immunotherapy with its PEPI technology platform, which uses computationally designed peptides that bind to multiple HLA types to trigger strong anti-tumor immune responses. The company's lead candidate, PolyPEPI1018 for colorectal cancer, has shown promising immunological and clinical signals in multiple trials. With a focus on creating accessible, off-the-shelf treatments, Treos aims to transform cancer care by making immunotherapies effective for broader patient groups and combinable with other standard therapies.

Therapeutic Areas